Previous 10 | Next 10 |
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it h...
2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...
2023-12-29 10:00:03 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, ...
2023-12-20 08:14:03 ET Polished ( POL ) +108% . Applied UV ( AUVI ) +30% . Longeveron ( LGVN ) +31% Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel- in the Treatment of Mild A...
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22,...
2023-11-15 09:50:09 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SciSparc Ltd (NASDAQ: SPRC), Chemomab Therapeutics Ltd (NASDAQ: CMMB), Cellectis SA (NASDAQ: CLLS), AstraZene...
2023-11-15 05:22:28 ET Cellectis ( NASDAQ: CLLS ) shares gained 9% premarket on Wednesday after the French biotech firm entered a binding agreement regarding the previously announced additional equity investment of $140M by AstraZeneca ( NASDAQ: AZN ). Earlier th...
2023-11-15 05:06:44 ET Related stories: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript JD.com: Catch The Falling Knife Again? Better Think Twice (Rating Downgrade) Tiger Global ...
Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023. Extraordinary shareholders’ meeting of Cellectis to be held on or around December 22, 2023 to approve such i...
2023-11-08 08:34:45 ET Lumos Pharma ( LUMO ) +36% Q3 earnings call release Target Hospitality ( TH ) +25% Q3 earnings call release Baiyu Holdings ( BYU ) +23% . Upwork ( UPWK ) +23% Q3 earnings call release EVgo ( E...
News, Short Squeeze, Breakout and More Instantly...
Cellectis S.A. Company Name:
CLLS Stock Symbol:
NASDAQ Market:
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 20...
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biote...
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering ...